Therapeutics for Rare and Neglected Diseases

May 20, 2009, the National Institutes of Health (NIH) launches the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases program, or TRND.

The program is unusual because TRND creates a drug development pipeline within the NIH and is specifically intended to stimulate research collaborations with academic scientists working on rare illnesses. The NIH Office of Rare Diseases Research (ORDR) will oversee the program, and TRND's laboratory operations will be administered by the National Human Genome Research Institute (NHGRI), which also operates the NIH Chemical Genomics Center (NCGC), a principal collaborator in TRND.

Transcript: http://www.genome.gov/Pages/Newsroom/CurrentNewsReleases/TRNDTranscript05-20-...

More: http://www.genome.gov/27531962

Category:

Science & Technology

Tags:

• NHGRI
• TRND
• NCGC
• ORDR
• NIH
• Therapeutics
• Rare
• Neglected
• Diseases